Cytomegalovirus infection during OKT3 treatment for renal allograft rejection.
Morgan
J D
JD
Department of Surgery, Leicester General Hospital, United Kingdom.
Horsburgh
T
T
Simpson
A
A
Donnelly
P K
PK
Veitch
P S
PS
Bell
P R
PR
D003586:Cytomegalovirus Infections / Q000188:drug therapy / Q000276:immunology* / Q000635:transmission; D004305:Dose-Response Relationship, Drug; D015774:Ganciclovir / Q000627:therapeutic use; D006084:Graft Rejection / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects / Q000276:immunology; D007677:Kidney Function Tests; D016030:Kidney Transplantation / Q000276:immunology*; D016853:Muromonab-CD3 / Q000008:administration & dosage* / Q000009:adverse effects; D009894:Opportunistic Infections / Q000276:immunology*; D011183:Postoperative Complications / Q000276:immunology / Q000628:therapy*; D014019:Tissue Donors
D016853:Muromonab-CD3; D015774:Ganciclovir